For the year ending 2025-12-31, BCAB had -$41,928K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -59,607 |
| Depreciation and amortization | 373 |
| Loss on disposal of property and equipment | -185 |
| Change in fair value of warrant liability | -295 |
| Change in fair value of ppas liability | 406 |
| Commitment fee under sepa | 282 |
| Financing costs related to ppas | 742 |
| Stock-based compensation | 5,434 |
| Prepaid expenses and other assets | -1,128 |
| Accounts payable and accrued expenses | 2,804 |
| Right-of-use assets and lease liabilities, net | 344 |
| Net cash used in operating activities | -48,204 |
| Proceeds from ppas | 7,125 |
| Payment of financing costs related to issuance of common stock, ppas and sepa | 897 |
| Proceeds from issuance of common stock and warrants, net of issuance costs | 0 |
| Proceeds from issuance of common stock under employee stock purchase plan | 100 |
| Payments for taxes related to net settlement of equity awards | 52 |
| Net cash provided by financing activities | 6,276 |
| Net decrease in cash and cash equivalents | -41,928 |
| Cash and cash equivalents, beginning of period | 49,046 |
| Cash and cash equivalents, end of period | 7,118 |
BioAtla, Inc. (BCAB)
BioAtla, Inc. (BCAB)